Epcoritamab Trial in Japanese R/R B-Cell NHL Shows Safety and Efficacy Potential
A trial is underway to assess the safety and efficacy of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Phase III
Oncology / B-Cell Non-Hodgkin Lymphoma
Status
Active
Sponsor
AbbVie
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma is significant as it may establish a new treatment option in a competitive market. Success could enhance Genmab's portfolio and strengthen its collaboration with AbbVie, impacting their market positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the determination of the RP2D and subsequent results from the expansion phase of the trial.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.